Evidence map›Paper›PMID 41410853›Full record

ReviewCardiovascular toxicology2025

Inventive HDL Mimicking Nanoparticles: A Promising Frontier in Cardiovascular Disease Management.

Shivani Ratra, Sunny Mukherjee, Sandipan Ray, Aimin Yu, Aravind Kumar Rengan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cardiovascular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shivani RatraDepartment of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, 502284, Telangana, India.
Sunny MukherjeeDepartment of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, 502284, Telangana, India.
Sandipan RayDepartment of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, Telangana, 502284, India.
Aimin YuDepartment of Chemistry & Biotechnology, Swinburne University of Technology, Hawthorn, VIC, 3122, Australia.
Aravind Kumar RenganDepartment of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, 502284, Telangana, India. aravind@bme.iith.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-density lipoproteins (HDLs) are endogenous nanoparticles critical for cholesterol transport, vascular protection, and immune modulation. Cardiovascular disease (CVD) often induces dysfunctional HDL, driving the emergence of HDL-mimicking nanoparticles (HMNPs)-engineered particles aiming to restore or enhance biological functions. This review details advances in HMNP design, including theranostic platforms and computational engineering, focusing on recent preclinical and clinical results. Key translational barriers such as manufacturing scale, regulatory complexity, population variability, and imaging agent toxicity are discussed, along with future opportunities in multi-target nanoplatforms and computational optimization. HMNPs show promise for advancing cardiovascular care by combining therapeutic and imaging capabilities, offering new hope for heart disease; however, further research is needed to overcome technical and clinical challenges and validate their real-world impact.

Indexed as

Biomimetic MaterialsCardiovascular DiseasesLipoproteins, HDLNanoparticlesAnimalsHumansTheranostic NanomedicineLipoproteins, HDLAtherosclerosisCardiovascular disease managementCholesterol effluxHDL mimicking nanoparticlesNanomedicine

Identifiers

PMID41410853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.